MAPT and Alzheimer disease: There were no group differences in AD biomarkers in blood (Aβ42, Aβ40) or CSF (BDNF, t‐tau, p‐tau181) (Table S1); notably, Aβ42/Aβ40 levels in blood and CSF remained stable over the 12‐month regardless of intervention group assignment (unadjusted means for AX and SBR in blood, baseline: 0.04, month 12: 0.04; and in CSF, baseline: 0.07, month 12: 0.07).